Terminated PHASE4 INTERVENTIONAL 1-arm NCT01648699

Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain

Study on the Effectiveness and Safety of OROS Hydromorphone in Pain Management Among Patients With Cancer Pain

Sponsor: Janssen Pharmaceutica

Conditions Pain

Interventions Osmotic Release Oral System (OROS) hydromorphone

Updated 7 times since 2017 Last updated: Oct 1, 2013 Started: Apr 30, 2010 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

the study was stopped due to non-availability of 4mg

Other terminated trials from Janssen Pharmaceutica

Alzheimer Disease · Phase PHASE1 · Feb 2022

See all terminations from Janssen Pharmaceutica

Other Pain trials with similar outcome

Browse all Pain trials

A PHASE4 clinical study on Pain, this trial is terminated or withdrawn. The trial is conducted by Janssen Pharmaceutica and has accumulated 7 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE4
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE4

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Pharmaceutica

Data source: Janssen Pharmaceutica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.